NAMS – newamsterdam pharma company n.v. - ordinary shares (US:NASDAQ)
Stock Stats
News
NewAmsterdam Pharma (NAMS) is now covered by Truist Financial Corporation. They set a "buy" rating and a $57.00 price target on the stock.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering [Yahoo! Finance]
NewAmsterdam Pharma (NASDAQ:NAMS) was downgraded by analysts at Wall Str
Form 4 NewAmsterdam Pharma Co For: Mar 11 Filed by: LANGE LOUIS G
Form 144 NewAmsterdam Pharma Co Filed by: LANGE LOUIS G
Form 4 NewAmsterdam Pharma Co For: Mar 06 Filed by: LANGE LOUIS G
Form 4 NewAmsterdam Pharma Co For: Mar 05 Filed by: Kastelein Johannes Jacob Pieter
Form 144 NewAmsterdam Pharma Co Filed by: LANGE LOUIS G
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.